Literature DB >> 10029251

Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys.

J E Schmitz1, M A Lifton, K A Reimann, D C Montefiori, L Shen, P Racz, K Tenner-Racz, M W Ollert, M A Forman, R S Gelman, C W Vogel, N L Letvin.   

Abstract

Cobra venom factor (CVF)-induced consumption of complement proteins was used to investigate the role of complement in vivo in the immunopathogenesis of simian immunodeficiency virus of macaques (SIVmac) infection in rhesus monkeys. Repeated administration of CVF was shown to deplete complement to <5% of baseline hemolytic activity of serum complement for 10 days in a normal monkey. Three groups of SIVmac-infected animals were then evaluated: monkeys treated with CVF resulting in complement depletion from days -1 to 10 postinfection, monkeys treated with CVF resulting in complement depletion from days 10 to 21 postinfection, and control monkeys that received no CVF. CD8+ SIVmac-specific cytotoxic T lymphocyte (CTL) generation and CD4+ T lymphocyte depletion during primary infection were not affected by CVF treatment. Viral load, assessed by measurements of plasma p27gag antigen and viral RNA, was transiently higher during the first 4 weeks following infection in the CVF-treated monkeys and the subsequent clinical course in these treated animals was accelerated. These results suggest that complement proteins may participate in immune defense mechanisms that decrease virus replication following the initial burst of intense viremia during primary SIVmac infection. However, we cannot rule out that the observed increased virus replication was induced by immune activation resulting from the administration of a foreign antigen to these monkeys.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029251     DOI: 10.1089/088922299311619

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  4 in total

1.  A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody.

Authors:  J E Schmitz; M A Simon; M J Kuroda; M A Lifton; M W Ollert; C W Vogel; P Racz; K Tenner-Racz; B J Scallon; M Dalesandro; J Ghrayeb; E P Rieber; V G Sasseville; K A Reimann
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics.

Authors:  R A Parker; M M Regan; K A Reimann
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.

Authors:  Jörn E Schmitz; Marcelo J Kuroda; Sampa Santra; Meredith A Simon; Michelle A Lifton; Wenyu Lin; Rajinder Khunkhun; Michael Piatak; Jeffrey D Lifson; Gudrun Grosschupff; Rebecca S Gelman; Paul Racz; Klara Tenner-Racz; Keith A Mansfield; Norman L Letvin; David C Montefiori; Keith A Reimann
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.

Authors:  Lars Hangartner; Raphaël M Zellweger; Mattia Giobbi; Jacqueline Weber; Bruno Eschli; Kathy D McCoy; Nicola Harris; Mike Recher; Rolf M Zinkernagel; Hans Hengartner
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.